Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/30/2025

Diagnostic Approach to Elevated Hemoglobin and Immature Granulocytes

Introduction to Myeloproliferative Neoplasms

  • The combination of elevated hemoglobin, hematocrit, red cell count, and increased immature granulocytes suggests either a primary myeloproliferative neoplasm or a severe secondary process, requiring immediate JAK2 mutation testing and hematology referral, as recommended by the American Society of Hematology 1, 2, 3

Diagnostic Criteria

  • Erythrocytosis is defined as hemoglobin >18.5 g/dL in men or >16.5 g/dL in women, and hematocrit >55% in men or >49.5% in women, according to the European Hematology Association 3
  • Myeloproliferative neoplasms, particularly polycythemia vera, are characterized by increased hemoglobin levels and thrombocytosis, with JAK2 mutations present in up to 97% of cases, as stated by the National Comprehensive Cancer Network 4, 3

Laboratory Workup

  • Complete blood count with differential is essential to quantify all cell lines, assess for basophilia, and determine blast percentage, as recommended by the College of American Pathologists 1, 2
  • JAK2 mutation testing is crucial to evaluate for polycythemia vera, and BCR-ABL testing is necessary to evaluate for chronic myeloid leukemia, according to the World Health Organization 3, 2

Diagnostic Algorithm

  • The presence of JAK2 mutation, BCR-ABL fusion gene, or other specific markers can help distinguish between primary myeloproliferative neoplasms and secondary causes, as outlined by the International Society for Laboratory Hematology 1, 2, 3

Management Considerations

  • Therapeutic phlebotomy is indicated when hemoglobin >20 g/dL and hematocrit >65% with associated hyperviscosity symptoms, after excluding dehydration, as recommended by the American College of Physicians 3
  • Maintenance of hematocrit <45% through phlebotomy is essential to reduce thrombotic risk in confirmed polycythemia vera, according to the European Society for Medical Oncology 3

Treatment of Underlying Conditions

  • Treatment of secondary causes, such as smoking cessation, CPAP therapy for obstructive sleep apnea, and management of COPD or chronic lung disease, is crucial to address the underlying condition, as recommended by the American Thoracic Society 3, 5
  • For confirmed polycythemia vera, maintenance of hematocrit <45% through therapeutic phlebotomy, low-dose aspirin, and consideration of cytoreductive therapy are essential, according to the National Institute for Health and Care Excellence 3
  • For chronic myeloid leukemia, tyrosine kinase inhibitor therapy, hydroxyurea for rapid cytoreduction, and regular monitoring with RT-Q-PCR for BCR-ABL transcript levels are necessary, as recommended by the European Society for Medical Oncology 1, 2, 3